Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2017-12

AUTHORS

Matthew J. Reilley, Ann Bailey, Vivek Subbiah, Filip Janku, Aung Naing, Gerald Falchook, Daniel Karp, Sarina Piha-Paul, Apostolia Tsimberidou, Siqing Fu, JoAnn Lim, Stacie Bean, Allison Bass, Sandra Montez, Luis Vence, Padmanee Sharma, James Allison, Funda Meric-Bernstam, David S. Hong

ABSTRACT

BACKGROUND: Imatinib mesylate can induce rapid tumor regression, increase tumor antigen presentation, and inhibit tumor immunosuppressive mechanisms. CTLA-4 blockade and imatinib synergize in mouse models to reduce tumor volume via intratumoral accumulation of CD8+ T cells. We hypothesized that imatinib combined with ipilimumab would be tolerable and may synergize in patients with advanced cancer. METHODS: Primary objective of the dose-escalation study (3 + 3 design) was to establish the maximum tolerated dose (MTD) and recommended phase II dose. Secondary objectives included evaluation of antitumor activity of the combination based on KIT mutation status and the capacity of tumor-associated immune biomarkers to predict response. RESULTS: The primary objective to establish the maximum tolerated dose (MTD) was achieved, and the recommended phase II doses are ipilimumab at 3 mg/kg every 3 weeks and imatinib 400 mg twice daily. Of the 35 patients treated in the escalation and GIST expansion, none experienced dose-limiting toxicities. The most common grade 1/2-related adverse events (AEs) were fatigue (66%), nausea (57%), anorexia, vomiting (each 31%), edema (29%), and anemia, diarrhea, and rash (each 23%). Grade 3 AEs occurred in 6 patients (17%) and included fatigue, anemia, fever, rash, and vomiting. There were no grade 4 AEs. In general, the combination was well tolerated. Among all patients, 2 responses were seen: 1 partial response (GIST) and 1 partial response (melanoma). Stable disease was seen in 6 patients lasting an average of 6 months. The melanoma responder was KIT mutated and the GIST responder was wild-type. CONCLUSIONS: Our findings suggest that this combination of a targeted agent with checkpoint blockade is safe across multiple tumor types. Low activity with no clear signal for synergy was observed in escalation or GIST expansion cohorts. Assessment of antitumor activity of this combination in the KIT-mutant melanoma population is being evaluated. TRIAL REGISTRATION: Clinicaltrials.gov NCT01738139, registered 28 November 2012. More... »

PAGES

35

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s40425-017-0238-1

DOI

http://dx.doi.org/10.1186/s40425-017-0238-1

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1084612708

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/28428884


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Imatinib Mesylate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Ipilimumab", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Young Adult", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "The University of Texas MD Anderson Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, 77030, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Reilley", 
        "givenName": "Matthew J.", 
        "id": "sg:person.01115740324.11", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01115740324.11"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The University of Texas MD Anderson Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, 77030, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bailey", 
        "givenName": "Ann", 
        "id": "sg:person.0747105374.37", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0747105374.37"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The University of Texas MD Anderson Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, 77030, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Subbiah", 
        "givenName": "Vivek", 
        "id": "sg:person.01164331266.84", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01164331266.84"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The University of Texas MD Anderson Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, 77030, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Janku", 
        "givenName": "Filip", 
        "id": "sg:person.01043330407.05", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01043330407.05"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The University of Texas MD Anderson Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, 77030, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Naing", 
        "givenName": "Aung", 
        "id": "sg:person.0740754276.55", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0740754276.55"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "HealthONE", 
          "id": "https://www.grid.ac/institutes/grid.489173.0", 
          "name": [
            "Sarah Cannon Research Institute at HealthOne, 1800 Williams Street, Suite 300, 80218, Denver, CO, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Falchook", 
        "givenName": "Gerald", 
        "id": "sg:person.0754516716.49", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0754516716.49"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The University of Texas MD Anderson Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, 77030, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Karp", 
        "givenName": "Daniel", 
        "id": "sg:person.01055341070.55", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01055341070.55"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The University of Texas MD Anderson Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, 77030, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Piha-Paul", 
        "givenName": "Sarina", 
        "id": "sg:person.01211050414.50", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01211050414.50"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The University of Texas MD Anderson Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, 77030, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tsimberidou", 
        "givenName": "Apostolia", 
        "id": "sg:person.013202454577.91", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013202454577.91"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The University of Texas MD Anderson Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, 77030, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fu", 
        "givenName": "Siqing", 
        "id": "sg:person.01255650125.08", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01255650125.08"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The University of Texas MD Anderson Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Pharamacy Clinical Programs, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, 77030, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lim", 
        "givenName": "JoAnn", 
        "id": "sg:person.016067172207.69", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016067172207.69"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The University of Texas MD Anderson Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Pharamacy Clinical Programs, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, 77030, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bean", 
        "givenName": "Stacie", 
        "id": "sg:person.012143707625.76", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012143707625.76"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The University of Texas MD Anderson Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Pharamacy Clinical Programs, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, 77030, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bass", 
        "givenName": "Allison", 
        "id": "sg:person.014607014033.45", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014607014033.45"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The University of Texas MD Anderson Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, 77030, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Montez", 
        "givenName": "Sandra", 
        "id": "sg:person.015404374433.76", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015404374433.76"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The University of Texas MD Anderson Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Immunology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, 77030, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Vence", 
        "givenName": "Luis", 
        "id": "sg:person.01121453457.02", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01121453457.02"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The University of Texas MD Anderson Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Immunology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, 77030, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sharma", 
        "givenName": "Padmanee", 
        "id": "sg:person.01302114057.99", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01302114057.99"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The University of Texas MD Anderson Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Immunology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, 77030, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Allison", 
        "givenName": "James", 
        "id": "sg:person.013745230632.15", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013745230632.15"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The University of Texas MD Anderson Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, 77030, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Meric-Bernstam", 
        "givenName": "Funda", 
        "id": "sg:person.01065126442.79", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01065126442.79"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The University of Texas MD Anderson Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, 77030, Houston, TX, USA", 
            "Department of Cancer Medicine, John Mendelsohn Faculty Center (FC8.3050), The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 0455, 77030, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hong", 
        "givenName": "David S.", 
        "id": "sg:person.01350131776.12", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01350131776.12"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1002/ijc.28625", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001284540"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nm.2438", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005333082", 
          "https://doi.org/10.1038/nm.2438"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2007.13.4452", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005473546"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1408440", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005474865"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-08-0575", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005810239"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s12916-015-0455-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007367199", 
          "https://doi.org/10.1186/s12916-015-0455-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2014.56.2736", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007733153"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1502309", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017367308"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1245/s10434-008-0177-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020576126", 
          "https://doi.org/10.1245/s10434-008-0177-7"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa020461", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022255922"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.surg.2015.10.021", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022869916"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/modpathol.2013.211", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026624345", 
          "https://doi.org/10.1038/modpathol.2013.211"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.30473", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027241413"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s004280000338", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027401391", 
          "https://doi.org/10.1007/s004280000338"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/0008-5472.can-13-0371", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027840095"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1182/blood-2004-01-0027", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030771434"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2015.61.6870", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031618095"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2012.47.7836", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031794892"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1535-7163.mct-14-0849", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036692449"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1535-7163.mct-09-0459", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037490992"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2014.56.6018", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038163219"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2010.33.9275", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038427267"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-14-1630", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038432075"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6604482", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1039293072", 
          "https://doi.org/10.1038/sj.bjc.6604482"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.25766", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040402237"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2006.06.2984", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041185282"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6604791", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044415363", 
          "https://doi.org/10.1038/sj.bjc.6604791"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1634/theoncologist.13-s4-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045339523"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1406037", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047704810"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1126/science.279.5350.577", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049612615"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1003466", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052212829"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1146/annurev.pathmechdis.3.121806.151538", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052964292"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2008.20.3869", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1053475114"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1126/science.1079666", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1062447255"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-16-2349", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1063225698"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.4161/onci.28925", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1072306701"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1083310898", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.30663", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084010655"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2016.34.15_suppl.9501", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1106842821"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2017-12", 
    "datePublishedReg": "2017-12-01", 
    "description": "BACKGROUND: Imatinib mesylate can induce rapid tumor regression, increase tumor antigen presentation, and inhibit tumor immunosuppressive mechanisms. CTLA-4 blockade and imatinib synergize in mouse models to reduce tumor volume via intratumoral accumulation of CD8+ T cells. We hypothesized that imatinib combined with ipilimumab would be tolerable and may synergize in patients with advanced cancer.\nMETHODS: Primary objective of the dose-escalation study (3\u2009+\u20093 design) was to establish the maximum tolerated dose (MTD) and recommended phase II dose. Secondary objectives included evaluation of antitumor activity of the combination based on KIT mutation status and the capacity of tumor-associated immune biomarkers to predict response.\nRESULTS: The primary objective to establish the maximum tolerated dose (MTD) was achieved, and the recommended phase II doses are ipilimumab at 3\u00a0mg/kg every 3\u00a0weeks and imatinib 400\u00a0mg twice daily. Of the 35 patients treated in the escalation and GIST expansion, none experienced dose-limiting toxicities. The most common grade 1/2-related adverse events (AEs) were fatigue (66%), nausea (57%), anorexia, vomiting (each 31%), edema (29%), and anemia, diarrhea, and rash (each 23%). Grade 3 AEs occurred in 6 patients (17%) and included fatigue, anemia, fever, rash, and vomiting. There were no grade 4 AEs. In general, the combination was well tolerated. Among all patients, 2 responses were seen: 1 partial response (GIST) and 1 partial response (melanoma). Stable disease was seen in 6 patients lasting an average of 6\u00a0months. The melanoma responder was KIT mutated and the GIST responder was wild-type.\nCONCLUSIONS: Our findings suggest that this combination of a targeted agent with checkpoint blockade is safe across multiple tumor types. Low activity with no clear signal for synergy was observed in escalation or GIST expansion cohorts. Assessment of antitumor activity of this combination in the KIT-mutant melanoma population is being evaluated.\nTRIAL REGISTRATION: Clinicaltrials.gov NCT01738139, registered 28 November 2012.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/s40425-017-0238-1", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1049249", 
        "issn": [
          "2051-1426"
        ], 
        "name": "Journal for ImmunoTherapy of Cancer", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "5"
      }
    ], 
    "name": "Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies", 
    "pagination": "35", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "0f51f836c80db0dd47bdf487d1532005461aaeafca190708fed56c2ae4393d10"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "28428884"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101620585"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s40425-017-0238-1"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1084612708"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s40425-017-0238-1", 
      "https://app.dimensions.ai/details/publication/pub.1084612708"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T09:54", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000347_0000000347/records_89798_00000002.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1186%2Fs40425-017-0238-1"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s40425-017-0238-1'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s40425-017-0238-1'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s40425-017-0238-1'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s40425-017-0238-1'


 

This table displays all metadata directly associated to this object as RDF triples.

369 TRIPLES      21 PREDICATES      79 URIs      32 LITERALS      20 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s40425-017-0238-1 schema:about N065ccf743d954b82bd1249e9e87b7e97
2 N14e1bd0301cf492585bb834a0b4bbaa8
3 N5550af7606a245c78f0f74f52bf2c11d
4 N60236a92e5f04d10a2547b6b3928846c
5 N89e38df4c0cc4927a3772929d3e3598e
6 N8c80e0d6a45540ddaad7fdcebb0943db
7 N96e52040f98c41bf9dc04b052f5b7009
8 Naf47953509604492830e90cfa6087e9f
9 Nb0dd7d2d3d324009ba1f0bb155e59bf3
10 Nc0d1f1a280044c8e9b1469e7cb968fee
11 Ndbd89cf2a8bb407abbd662a61d17bad7
12 anzsrc-for:11
13 anzsrc-for:1112
14 schema:author N6728ea0fe1434ae7b3ce93de4bc95d0f
15 schema:citation sg:pub.10.1007/s004280000338
16 sg:pub.10.1038/modpathol.2013.211
17 sg:pub.10.1038/nm.2438
18 sg:pub.10.1038/sj.bjc.6604482
19 sg:pub.10.1038/sj.bjc.6604791
20 sg:pub.10.1186/s12916-015-0455-8
21 sg:pub.10.1245/s10434-008-0177-7
22 https://app.dimensions.ai/details/publication/pub.1083310898
23 https://doi.org/10.1002/cncr.25766
24 https://doi.org/10.1002/cncr.30473
25 https://doi.org/10.1002/cncr.30663
26 https://doi.org/10.1002/ijc.28625
27 https://doi.org/10.1016/j.surg.2015.10.021
28 https://doi.org/10.1056/nejmoa020461
29 https://doi.org/10.1056/nejmoa1003466
30 https://doi.org/10.1056/nejmoa1406037
31 https://doi.org/10.1056/nejmoa1408440
32 https://doi.org/10.1056/nejmoa1502309
33 https://doi.org/10.1126/science.1079666
34 https://doi.org/10.1126/science.279.5350.577
35 https://doi.org/10.1146/annurev.pathmechdis.3.121806.151538
36 https://doi.org/10.1158/0008-5472.can-13-0371
37 https://doi.org/10.1158/1078-0432.ccr-08-0575
38 https://doi.org/10.1158/1078-0432.ccr-14-1630
39 https://doi.org/10.1158/1078-0432.ccr-16-2349
40 https://doi.org/10.1158/1535-7163.mct-09-0459
41 https://doi.org/10.1158/1535-7163.mct-14-0849
42 https://doi.org/10.1182/blood-2004-01-0027
43 https://doi.org/10.1200/jco.2006.06.2984
44 https://doi.org/10.1200/jco.2007.13.4452
45 https://doi.org/10.1200/jco.2008.20.3869
46 https://doi.org/10.1200/jco.2010.33.9275
47 https://doi.org/10.1200/jco.2012.47.7836
48 https://doi.org/10.1200/jco.2014.56.2736
49 https://doi.org/10.1200/jco.2014.56.6018
50 https://doi.org/10.1200/jco.2015.61.6870
51 https://doi.org/10.1200/jco.2016.34.15_suppl.9501
52 https://doi.org/10.1634/theoncologist.13-s4-2
53 https://doi.org/10.4161/onci.28925
54 schema:datePublished 2017-12
55 schema:datePublishedReg 2017-12-01
56 schema:description BACKGROUND: Imatinib mesylate can induce rapid tumor regression, increase tumor antigen presentation, and inhibit tumor immunosuppressive mechanisms. CTLA-4 blockade and imatinib synergize in mouse models to reduce tumor volume via intratumoral accumulation of CD8+ T cells. We hypothesized that imatinib combined with ipilimumab would be tolerable and may synergize in patients with advanced cancer. METHODS: Primary objective of the dose-escalation study (3 + 3 design) was to establish the maximum tolerated dose (MTD) and recommended phase II dose. Secondary objectives included evaluation of antitumor activity of the combination based on KIT mutation status and the capacity of tumor-associated immune biomarkers to predict response. RESULTS: The primary objective to establish the maximum tolerated dose (MTD) was achieved, and the recommended phase II doses are ipilimumab at 3 mg/kg every 3 weeks and imatinib 400 mg twice daily. Of the 35 patients treated in the escalation and GIST expansion, none experienced dose-limiting toxicities. The most common grade 1/2-related adverse events (AEs) were fatigue (66%), nausea (57%), anorexia, vomiting (each 31%), edema (29%), and anemia, diarrhea, and rash (each 23%). Grade 3 AEs occurred in 6 patients (17%) and included fatigue, anemia, fever, rash, and vomiting. There were no grade 4 AEs. In general, the combination was well tolerated. Among all patients, 2 responses were seen: 1 partial response (GIST) and 1 partial response (melanoma). Stable disease was seen in 6 patients lasting an average of 6 months. The melanoma responder was KIT mutated and the GIST responder was wild-type. CONCLUSIONS: Our findings suggest that this combination of a targeted agent with checkpoint blockade is safe across multiple tumor types. Low activity with no clear signal for synergy was observed in escalation or GIST expansion cohorts. Assessment of antitumor activity of this combination in the KIT-mutant melanoma population is being evaluated. TRIAL REGISTRATION: Clinicaltrials.gov NCT01738139, registered 28 November 2012.
57 schema:genre research_article
58 schema:inLanguage en
59 schema:isAccessibleForFree true
60 schema:isPartOf N232ddcb18efb42399fecbecebe9e44b0
61 N5afeddd94ad84552a18b2a6cb79fc826
62 sg:journal.1049249
63 schema:name Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies
64 schema:pagination 35
65 schema:productId N6a8226a1fbc6492691641bb41efc2ecf
66 N73f6552b83b64447a3bb85e793bc11ee
67 N934a272ab47349269234caba222535f5
68 Nf96e3fa80e3843eca8f31eca8d67a9bd
69 Nfc52acdb1834411e9c6eac5dab5a8097
70 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084612708
71 https://doi.org/10.1186/s40425-017-0238-1
72 schema:sdDatePublished 2019-04-11T09:54
73 schema:sdLicense https://scigraph.springernature.com/explorer/license/
74 schema:sdPublisher N11f12ad469aa49a6a2df237a82ade3e1
75 schema:url https://link.springer.com/10.1186%2Fs40425-017-0238-1
76 sgo:license sg:explorer/license/
77 sgo:sdDataset articles
78 rdf:type schema:ScholarlyArticle
79 N065ccf743d954b82bd1249e9e87b7e97 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
80 schema:name Imatinib Mesylate
81 rdf:type schema:DefinedTerm
82 N098aab9e273c4b41b78560a7bf85ac2e rdf:first sg:person.013745230632.15
83 rdf:rest N5412283c7e61462c8fa1f57ba9069549
84 N11f12ad469aa49a6a2df237a82ade3e1 schema:name Springer Nature - SN SciGraph project
85 rdf:type schema:Organization
86 N14e1bd0301cf492585bb834a0b4bbaa8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
87 schema:name Adult
88 rdf:type schema:DefinedTerm
89 N232ddcb18efb42399fecbecebe9e44b0 schema:issueNumber 1
90 rdf:type schema:PublicationIssue
91 N2ce50d123c274bc78291259c718a605f rdf:first sg:person.01164331266.84
92 rdf:rest N7f91599edaf04d6589fc0b553a9488e4
93 N3c5e4f1cfae54125928a6d57fa5ca904 rdf:first sg:person.01211050414.50
94 rdf:rest Nc03a19518228446780a5e94d82cc135e
95 N46a7651da3654fadaee226ad80422236 rdf:first sg:person.0740754276.55
96 rdf:rest N6cd6581b380844d48a93afaf2274fa46
97 N5412283c7e61462c8fa1f57ba9069549 rdf:first sg:person.01065126442.79
98 rdf:rest Nbc4a051fb8374decbb941ef74b6748bb
99 N5550af7606a245c78f0f74f52bf2c11d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
100 schema:name Neoplasms
101 rdf:type schema:DefinedTerm
102 N5afeddd94ad84552a18b2a6cb79fc826 schema:volumeNumber 5
103 rdf:type schema:PublicationVolume
104 N60236a92e5f04d10a2547b6b3928846c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
105 schema:name Young Adult
106 rdf:type schema:DefinedTerm
107 N6299471e7a2d45b48aa651b9eb51ab0e rdf:first sg:person.01255650125.08
108 rdf:rest N82577ae40d6b428794b24979cf032ad8
109 N6728ea0fe1434ae7b3ce93de4bc95d0f rdf:first sg:person.01115740324.11
110 rdf:rest Ndd6a5a8a7aac4ee3af442b4604623615
111 N6a8226a1fbc6492691641bb41efc2ecf schema:name nlm_unique_id
112 schema:value 101620585
113 rdf:type schema:PropertyValue
114 N6cd6581b380844d48a93afaf2274fa46 rdf:first sg:person.0754516716.49
115 rdf:rest Ne3415ecc207942c8819cf48a9b29abb7
116 N73f6552b83b64447a3bb85e793bc11ee schema:name doi
117 schema:value 10.1186/s40425-017-0238-1
118 rdf:type schema:PropertyValue
119 N77a0c2fada9b4f48b5616c585baf2297 rdf:first sg:person.014607014033.45
120 rdf:rest N8d08ede4223444b4b18c7dd8a53e228c
121 N7f91599edaf04d6589fc0b553a9488e4 rdf:first sg:person.01043330407.05
122 rdf:rest N46a7651da3654fadaee226ad80422236
123 N7ff19978cb1b400bb394f0dcf9cb35be rdf:first sg:person.01302114057.99
124 rdf:rest N098aab9e273c4b41b78560a7bf85ac2e
125 N82577ae40d6b428794b24979cf032ad8 rdf:first sg:person.016067172207.69
126 rdf:rest N9260a858cb604a4b9dee6f7a7c5cfacf
127 N89e38df4c0cc4927a3772929d3e3598e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Female
129 rdf:type schema:DefinedTerm
130 N8c80e0d6a45540ddaad7fdcebb0943db schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Male
132 rdf:type schema:DefinedTerm
133 N8d08ede4223444b4b18c7dd8a53e228c rdf:first sg:person.015404374433.76
134 rdf:rest Nbb5e6e16687b4e799f98cc04234498db
135 N9260a858cb604a4b9dee6f7a7c5cfacf rdf:first sg:person.012143707625.76
136 rdf:rest N77a0c2fada9b4f48b5616c585baf2297
137 N934a272ab47349269234caba222535f5 schema:name pubmed_id
138 schema:value 28428884
139 rdf:type schema:PropertyValue
140 N96e52040f98c41bf9dc04b052f5b7009 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Aged
142 rdf:type schema:DefinedTerm
143 Naf47953509604492830e90cfa6087e9f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Ipilimumab
145 rdf:type schema:DefinedTerm
146 Nb0dd7d2d3d324009ba1f0bb155e59bf3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Humans
148 rdf:type schema:DefinedTerm
149 Nbb5e6e16687b4e799f98cc04234498db rdf:first sg:person.01121453457.02
150 rdf:rest N7ff19978cb1b400bb394f0dcf9cb35be
151 Nbc4a051fb8374decbb941ef74b6748bb rdf:first sg:person.01350131776.12
152 rdf:rest rdf:nil
153 Nc03a19518228446780a5e94d82cc135e rdf:first sg:person.013202454577.91
154 rdf:rest N6299471e7a2d45b48aa651b9eb51ab0e
155 Nc0d1f1a280044c8e9b1469e7cb968fee schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Antineoplastic Combined Chemotherapy Protocols
157 rdf:type schema:DefinedTerm
158 Ndbd89cf2a8bb407abbd662a61d17bad7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Middle Aged
160 rdf:type schema:DefinedTerm
161 Ndd6a5a8a7aac4ee3af442b4604623615 rdf:first sg:person.0747105374.37
162 rdf:rest N2ce50d123c274bc78291259c718a605f
163 Ne3415ecc207942c8819cf48a9b29abb7 rdf:first sg:person.01055341070.55
164 rdf:rest N3c5e4f1cfae54125928a6d57fa5ca904
165 Nf96e3fa80e3843eca8f31eca8d67a9bd schema:name readcube_id
166 schema:value 0f51f836c80db0dd47bdf487d1532005461aaeafca190708fed56c2ae4393d10
167 rdf:type schema:PropertyValue
168 Nfc52acdb1834411e9c6eac5dab5a8097 schema:name dimensions_id
169 schema:value pub.1084612708
170 rdf:type schema:PropertyValue
171 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
172 schema:name Medical and Health Sciences
173 rdf:type schema:DefinedTerm
174 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
175 schema:name Oncology and Carcinogenesis
176 rdf:type schema:DefinedTerm
177 sg:journal.1049249 schema:issn 2051-1426
178 schema:name Journal for ImmunoTherapy of Cancer
179 rdf:type schema:Periodical
180 sg:person.01043330407.05 schema:affiliation https://www.grid.ac/institutes/grid.240145.6
181 schema:familyName Janku
182 schema:givenName Filip
183 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01043330407.05
184 rdf:type schema:Person
185 sg:person.01055341070.55 schema:affiliation https://www.grid.ac/institutes/grid.240145.6
186 schema:familyName Karp
187 schema:givenName Daniel
188 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01055341070.55
189 rdf:type schema:Person
190 sg:person.01065126442.79 schema:affiliation https://www.grid.ac/institutes/grid.240145.6
191 schema:familyName Meric-Bernstam
192 schema:givenName Funda
193 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01065126442.79
194 rdf:type schema:Person
195 sg:person.01115740324.11 schema:affiliation https://www.grid.ac/institutes/grid.240145.6
196 schema:familyName Reilley
197 schema:givenName Matthew J.
198 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01115740324.11
199 rdf:type schema:Person
200 sg:person.01121453457.02 schema:affiliation https://www.grid.ac/institutes/grid.240145.6
201 schema:familyName Vence
202 schema:givenName Luis
203 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01121453457.02
204 rdf:type schema:Person
205 sg:person.01164331266.84 schema:affiliation https://www.grid.ac/institutes/grid.240145.6
206 schema:familyName Subbiah
207 schema:givenName Vivek
208 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01164331266.84
209 rdf:type schema:Person
210 sg:person.01211050414.50 schema:affiliation https://www.grid.ac/institutes/grid.240145.6
211 schema:familyName Piha-Paul
212 schema:givenName Sarina
213 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01211050414.50
214 rdf:type schema:Person
215 sg:person.012143707625.76 schema:affiliation https://www.grid.ac/institutes/grid.240145.6
216 schema:familyName Bean
217 schema:givenName Stacie
218 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012143707625.76
219 rdf:type schema:Person
220 sg:person.01255650125.08 schema:affiliation https://www.grid.ac/institutes/grid.240145.6
221 schema:familyName Fu
222 schema:givenName Siqing
223 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01255650125.08
224 rdf:type schema:Person
225 sg:person.01302114057.99 schema:affiliation https://www.grid.ac/institutes/grid.240145.6
226 schema:familyName Sharma
227 schema:givenName Padmanee
228 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01302114057.99
229 rdf:type schema:Person
230 sg:person.013202454577.91 schema:affiliation https://www.grid.ac/institutes/grid.240145.6
231 schema:familyName Tsimberidou
232 schema:givenName Apostolia
233 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013202454577.91
234 rdf:type schema:Person
235 sg:person.01350131776.12 schema:affiliation https://www.grid.ac/institutes/grid.240145.6
236 schema:familyName Hong
237 schema:givenName David S.
238 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01350131776.12
239 rdf:type schema:Person
240 sg:person.013745230632.15 schema:affiliation https://www.grid.ac/institutes/grid.240145.6
241 schema:familyName Allison
242 schema:givenName James
243 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013745230632.15
244 rdf:type schema:Person
245 sg:person.014607014033.45 schema:affiliation https://www.grid.ac/institutes/grid.240145.6
246 schema:familyName Bass
247 schema:givenName Allison
248 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014607014033.45
249 rdf:type schema:Person
250 sg:person.015404374433.76 schema:affiliation https://www.grid.ac/institutes/grid.240145.6
251 schema:familyName Montez
252 schema:givenName Sandra
253 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015404374433.76
254 rdf:type schema:Person
255 sg:person.016067172207.69 schema:affiliation https://www.grid.ac/institutes/grid.240145.6
256 schema:familyName Lim
257 schema:givenName JoAnn
258 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016067172207.69
259 rdf:type schema:Person
260 sg:person.0740754276.55 schema:affiliation https://www.grid.ac/institutes/grid.240145.6
261 schema:familyName Naing
262 schema:givenName Aung
263 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0740754276.55
264 rdf:type schema:Person
265 sg:person.0747105374.37 schema:affiliation https://www.grid.ac/institutes/grid.240145.6
266 schema:familyName Bailey
267 schema:givenName Ann
268 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0747105374.37
269 rdf:type schema:Person
270 sg:person.0754516716.49 schema:affiliation https://www.grid.ac/institutes/grid.489173.0
271 schema:familyName Falchook
272 schema:givenName Gerald
273 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0754516716.49
274 rdf:type schema:Person
275 sg:pub.10.1007/s004280000338 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027401391
276 https://doi.org/10.1007/s004280000338
277 rdf:type schema:CreativeWork
278 sg:pub.10.1038/modpathol.2013.211 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026624345
279 https://doi.org/10.1038/modpathol.2013.211
280 rdf:type schema:CreativeWork
281 sg:pub.10.1038/nm.2438 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005333082
282 https://doi.org/10.1038/nm.2438
283 rdf:type schema:CreativeWork
284 sg:pub.10.1038/sj.bjc.6604482 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039293072
285 https://doi.org/10.1038/sj.bjc.6604482
286 rdf:type schema:CreativeWork
287 sg:pub.10.1038/sj.bjc.6604791 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044415363
288 https://doi.org/10.1038/sj.bjc.6604791
289 rdf:type schema:CreativeWork
290 sg:pub.10.1186/s12916-015-0455-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007367199
291 https://doi.org/10.1186/s12916-015-0455-8
292 rdf:type schema:CreativeWork
293 sg:pub.10.1245/s10434-008-0177-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020576126
294 https://doi.org/10.1245/s10434-008-0177-7
295 rdf:type schema:CreativeWork
296 https://app.dimensions.ai/details/publication/pub.1083310898 schema:CreativeWork
297 https://doi.org/10.1002/cncr.25766 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040402237
298 rdf:type schema:CreativeWork
299 https://doi.org/10.1002/cncr.30473 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027241413
300 rdf:type schema:CreativeWork
301 https://doi.org/10.1002/cncr.30663 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084010655
302 rdf:type schema:CreativeWork
303 https://doi.org/10.1002/ijc.28625 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001284540
304 rdf:type schema:CreativeWork
305 https://doi.org/10.1016/j.surg.2015.10.021 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022869916
306 rdf:type schema:CreativeWork
307 https://doi.org/10.1056/nejmoa020461 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022255922
308 rdf:type schema:CreativeWork
309 https://doi.org/10.1056/nejmoa1003466 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052212829
310 rdf:type schema:CreativeWork
311 https://doi.org/10.1056/nejmoa1406037 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047704810
312 rdf:type schema:CreativeWork
313 https://doi.org/10.1056/nejmoa1408440 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005474865
314 rdf:type schema:CreativeWork
315 https://doi.org/10.1056/nejmoa1502309 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017367308
316 rdf:type schema:CreativeWork
317 https://doi.org/10.1126/science.1079666 schema:sameAs https://app.dimensions.ai/details/publication/pub.1062447255
318 rdf:type schema:CreativeWork
319 https://doi.org/10.1126/science.279.5350.577 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049612615
320 rdf:type schema:CreativeWork
321 https://doi.org/10.1146/annurev.pathmechdis.3.121806.151538 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052964292
322 rdf:type schema:CreativeWork
323 https://doi.org/10.1158/0008-5472.can-13-0371 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027840095
324 rdf:type schema:CreativeWork
325 https://doi.org/10.1158/1078-0432.ccr-08-0575 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005810239
326 rdf:type schema:CreativeWork
327 https://doi.org/10.1158/1078-0432.ccr-14-1630 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038432075
328 rdf:type schema:CreativeWork
329 https://doi.org/10.1158/1078-0432.ccr-16-2349 schema:sameAs https://app.dimensions.ai/details/publication/pub.1063225698
330 rdf:type schema:CreativeWork
331 https://doi.org/10.1158/1535-7163.mct-09-0459 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037490992
332 rdf:type schema:CreativeWork
333 https://doi.org/10.1158/1535-7163.mct-14-0849 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036692449
334 rdf:type schema:CreativeWork
335 https://doi.org/10.1182/blood-2004-01-0027 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030771434
336 rdf:type schema:CreativeWork
337 https://doi.org/10.1200/jco.2006.06.2984 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041185282
338 rdf:type schema:CreativeWork
339 https://doi.org/10.1200/jco.2007.13.4452 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005473546
340 rdf:type schema:CreativeWork
341 https://doi.org/10.1200/jco.2008.20.3869 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053475114
342 rdf:type schema:CreativeWork
343 https://doi.org/10.1200/jco.2010.33.9275 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038427267
344 rdf:type schema:CreativeWork
345 https://doi.org/10.1200/jco.2012.47.7836 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031794892
346 rdf:type schema:CreativeWork
347 https://doi.org/10.1200/jco.2014.56.2736 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007733153
348 rdf:type schema:CreativeWork
349 https://doi.org/10.1200/jco.2014.56.6018 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038163219
350 rdf:type schema:CreativeWork
351 https://doi.org/10.1200/jco.2015.61.6870 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031618095
352 rdf:type schema:CreativeWork
353 https://doi.org/10.1200/jco.2016.34.15_suppl.9501 schema:sameAs https://app.dimensions.ai/details/publication/pub.1106842821
354 rdf:type schema:CreativeWork
355 https://doi.org/10.1634/theoncologist.13-s4-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045339523
356 rdf:type schema:CreativeWork
357 https://doi.org/10.4161/onci.28925 schema:sameAs https://app.dimensions.ai/details/publication/pub.1072306701
358 rdf:type schema:CreativeWork
359 https://www.grid.ac/institutes/grid.240145.6 schema:alternateName The University of Texas MD Anderson Cancer Center
360 schema:name Department of Cancer Medicine, John Mendelsohn Faculty Center (FC8.3050), The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Unit 0455, 77030, Houston, TX, USA
361 Department of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, 77030, Houston, TX, USA
362 Department of Immunology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, 77030, Houston, TX, USA
363 Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, 77030, Houston, TX, USA
364 Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, 77030, Houston, TX, USA
365 Pharamacy Clinical Programs, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, 77030, Houston, TX, USA
366 rdf:type schema:Organization
367 https://www.grid.ac/institutes/grid.489173.0 schema:alternateName HealthONE
368 schema:name Sarah Cannon Research Institute at HealthOne, 1800 Williams Street, Suite 300, 80218, Denver, CO, USA
369 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...